Skip to main content
SpringerLink
Log in

MR imaging of the prostate in clinical practice

  • Review Article
  • Published:
Magnetic Resonance Materials in Physics, Biology and Medicine Aims and scope Submit manuscript

Abstract

Magnetic resonance imaging (MRI) is the imaging tool of choice in the evaluation of prostate cancer. The main applications of MR imaging in the management of prostate cancer are: (1) to guide targeted biopsy when prostate cancer is clinically suspected and previous ultrasound-guided biopsy results are negative; (2) to localize and stage prostate cancer and provide a roadmap for treatment planning; and (3) to detect residual or locally recurrent cancer after treatment. Other MR techniques such as proton MR spectroscopic imaging (MRSI), diffusion-weighted imaging (DWI), and contrast-enhanced MRI (CE-MRI) complement conventional MR imaging by providing metabolic and functional information that can improve the accuracy of prostate cancer detection and characterization. In everyday clinical practice, and to account for patient comfort, MR imaging studies are limited to 1 h. To obtain consistently high-quality images, a well-designed protocol is necessary. Routine MR imaging can be supplemented by other MR techniques such as MRSI, DWI or CE-MRI depending on the expertise available and the clinical questions that need to be answered. This review summarizes the role of MR imaging in the management of prostate cancer and describes practical approaches to implementing anatomic, metabolic and functional MR imaging techniques in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society (2008) Cancer facts and figures 2008. American Cancer Society, Atlanta

    Google Scholar 

  2. Kurhanewicz J, Swanson MG, Wood PJ, Vigneron DB (2001) Magnetic resonance imaging and spectroscopic imaging: improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials. Urology 57(4 Suppl 1): 124–128

    PubMed  CAS  Google Scholar 

  3. Taneja SS (2006) Prostate biopsy: targeting cancer for detection and therapy. Rev Urol 8(4): 173–182

    PubMed  Google Scholar 

  4. Yu KK, Hricak H (2000) Imaging prostate cancer. Radiol Clin North Am 38(1): 59–85 viii

    PubMed  Google Scholar 

  5. Wang L, Mullerad M, Chen HN, Eberhardt SC, Kattan MW, Scardino PT, Hricak H (2004) Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 232(1): 133–139

    PubMed  Google Scholar 

  6. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J (1999) Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging–clinicopathologic study. Radiology 213(2): 473–480

    PubMed  CAS  Google Scholar 

  7. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58(6): 843–848

    PubMed  CAS  Google Scholar 

  8. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT (1997) Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79(3): 528–537

    PubMed  CAS  Google Scholar 

  9. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Huland H, Scardino PT, Kattan MW (2002) A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 7(4): 141–146

    PubMed  Google Scholar 

  10. Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Debre B, Zerbib M (2005) Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 47(5): 582–586

    PubMed  Google Scholar 

  11. Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M (2005) MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology 234(2): 576–581

    PubMed  Google Scholar 

  12. Kaplan I, Oldenburg NE, Meskell P, Blake M, Church P, Holupka EJ (2002) Real time MRI-ultrasound image guided stereotactic prostate biopsy. Magn Reson Imaging 20(3): 295–299

    PubMed  Google Scholar 

  13. Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen HN, Kattan MW, Scardino PT (2005) Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 174(6): 2158–2163

    PubMed  Google Scholar 

  14. Zakian KL, Eberhardt S, Hricak H, Shukla-Dave A, Kleinman S, Muruganandham M, Sircar K, Kattan MW, Reuter VE, Scardino PT, Koutcher JA (2003) Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging–initial results. Radiology 229(1): 241–247

    PubMed  Google Scholar 

  15. Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, Pucar D, Scardino PT, Hricak H (2006) Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 239(3): 784–792

    PubMed  Google Scholar 

  16. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, Nelson SJ, Carroll PR, Kurhanewicz J (1999) Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213(2): 481–488

    PubMed  CAS  Google Scholar 

  17. D’Amico AV, Cormack RA, Tempany CM (2001) MRI-guided diagnosis and treatment of prostate cancer. N Eng J Med 344(10): 776–777

    CAS  Google Scholar 

  18. Cornud F, Flam T, Chauveinc L, Hamida K, Chretien Y, Vieillefond A, Helenon O, Moreau JF (2002) Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 224(1): 203–210

    PubMed  Google Scholar 

  19. Gibbons RP, Correa RJ Jr, Brannen GE, Weissman RM (1989) Total prostatectomy for clinically localized prostatic cancer: long-term results. J Urol 141(3): 564–566

    PubMed  CAS  Google Scholar 

  20. Chodak G (1994) Conservative management of clinically-localized prostate cancer. Can J Oncol 4(Suppl 1): 20–21 (discussion 22–23)

    Google Scholar 

  21. Epstein JI, Carmichael MJ, Pizov G, Walsh PC (1993) Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 150(1): 135–141

    PubMed  CAS  Google Scholar 

  22. Hricak H, Wang L, Wei DC, Coakley FV, Akin O, Reuter VE, Gonen M, Kattan MW, Onyebuchi CN, Scardino PT (2004) The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 100(12): 2655–2663

    PubMed  Google Scholar 

  23. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO (2002) Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12(9): 2294–2302

    PubMed  Google Scholar 

  24. Tempany CM (1996) MR staging of prostate cancer. How we can improve our accuracy with decisions aids and optimal techniques. Magn Reson Imaging Clin North Am 4(3): 519–532

    CAS  Google Scholar 

  25. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ (1997) Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 202(3): 697–702

    PubMed  CAS  Google Scholar 

  26. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT (2004) Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 232(1): 140–146

    PubMed  Google Scholar 

  27. Bloch BN, Furman-Haran E, Helbich TH, Lenkinski RE, Degani H, Kratzik C, Susani M, Haitel A, Jaromi S, Ngo L, Rofsky NM (2007) Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging–initial results. Radiology 245(1): 176–185

    PubMed  Google Scholar 

  28. Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisenberg HF, Scardino PT (2007) Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 242(1): 182–188

    PubMed  Google Scholar 

  29. Futterer JJ, Heijmink SW, Scheenen TW, Jager GJ, Hulsbergen-Vande Kaa CA, Witjes JA, Barentsz JO (2006) Prostate cancer: local staging at 3-T endorectal MR imaging–early experience. Radiology 238(1): 184–191

    PubMed  Google Scholar 

  30. Rorvik J, Halvorsen OJ, Albrektsen G, Ersland L, Daehlin L, Haukaas S (1999) MRI with an endorectal coil for staging of clinically localised prostate cancer prior to radical prostatectomy. Eur Radiol 9(1): 29–34

    PubMed  CAS  Google Scholar 

  31. Kattan MW, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17(5): 1499–1507

    PubMed  CAS  Google Scholar 

  32. D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Tomaszewski JE, Wein A (1998) The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 160(6 Pt 1): 2096–2101

    PubMed  CAS  Google Scholar 

  33. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43(5): 649–659

    PubMed  CAS  Google Scholar 

  34. Cooperberg MR, Koppie TM, Lubeck DP, Ye J, Grossfeld GD, Mehta SS, Carroll PR (2003) How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE. Urology 61(1): 190–196

    PubMed  Google Scholar 

  35. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231(2): 379–385

    PubMed  Google Scholar 

  36. Sala E, Eberhardt SC, Akin O, Moskowitz CS, Onyebuchi CN, Kuroiwa K, Ishill N, Zelefsky MJ, Eastham JA, Hricak H (2006) Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 238(1): 176–183

    PubMed  Google Scholar 

  37. Hricak H, White S, Vigneron D, Kurhanewicz J, Kosco A, Levin D, Weiss J, Narayan P, Carroll PR (1994) Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal–pelvic phased-array coils. Radiology 193(3): 703–709

    PubMed  CAS  Google Scholar 

  38. Rosen Y, Bloch BN, Lenkinski RE, Greenman RL, Marquis RP, Rofsky NM (2007) 3T MR of the prostate: reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension. Magn Reson Med 57(5): 898–904

    PubMed  CAS  Google Scholar 

  39. Brown JJ, Duncan JR, Heiken JP, Balfe DM, Corr AP, Mirowitz SA, Eilenberg SS, Lee JK (1991) Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon. Radiology 181(2): 455–460

    PubMed  CAS  Google Scholar 

  40. Mitchell DG, Vinitski S, Mohamed FB, Mammone JF, Haidet K, Rifkin MD (1991) Comparison of Kaopectate with barium for negative and positive enteric contrast at MR imaging. Radiology 181(2): 475–480

    PubMed  CAS  Google Scholar 

  41. Panaccione JL, Ros PR, Torres GM, Burton SS (1991) Rectal barium in pelvic MR imaging: initial results. J Magn Reson Imaging 1(5): 605–607

    PubMed  CAS  Google Scholar 

  42. Kaji Y, Kurhanewicz J, Hricak H, Sokolov DL, Huang LR, Nelson SJ, Vigneron DB (1998) Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 206(3): 785–790

    PubMed  CAS  Google Scholar 

  43. White S, Hricak H, Forstner R, Kurhanewicz J, Vigneron DB, Zaloudek CJ, Weiss JM, Narayan P, Carroll PR (1995) Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 195(2): 385–390

    PubMed  CAS  Google Scholar 

  44. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, Carroll PR, Kurhanewicz J (2004) Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR 183(4): 1079–1083

    PubMed  Google Scholar 

  45. Schnall MD, Pollack HM (1990) Magnetic resonance imaging of the prostate gland. Urol Radiol 12(2): 109–114

    PubMed  CAS  Google Scholar 

  46. Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, Hulsbergen-Vande Kaa CA, Witjes JA, Krabbe PF, Heerschap A, Barentsz JO (2006) Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241(2): 449–458

    PubMed  Google Scholar 

  47. Singh AK, Kruecker J, Xu S, Glossop N, Guion P, Ullman K, Choyke PL, Wood BJ (2008) Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int 101: 841–845

    PubMed  Google Scholar 

  48. Rouviere O, Hartman RP, Lyonnet D (2006) Prostate MR imaging at high-field strength: evolution or revolution?. Eur Radiol 16(2): 276–284

    PubMed  Google Scholar 

  49. Futterer JJ, Scheenen TW, Huisman HJ, Klomp DW, van Dorsten FA, Hulsbergen-van de Kaa CA, Witjes JA, Heerschap A, Barentsz JO (2004) Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 39(11): 671–680

    PubMed  Google Scholar 

  50. Sosna J, Pedrosa I, Dewolf WC, Mahallati H, Lenkinski RE, Rofsky NM (2004) MR imaging of the prostate at 3 Tesla: comparison of an external phased-array coil to imaging with an endorectal coil at 1.5 Tesla. Acad Radiol 11(8): 857–862

    PubMed  Google Scholar 

  51. Heijmink SW, Futterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ, Hulsbergen-Van de Kaa CA, Knipscheer BC, Kiemeney LA, Witjes JA, Barentsz JO (2007) Prostate cancer: body-array versus endorectal coil MR imaging at 3 T–comparison of image quality, localization, and staging performance. Radiology 244(1): 184–195

    PubMed  Google Scholar 

  52. Cornfeld DM, Weinreb JC (2007) MR imaging of the prostate: 5 T versus 3 T. Magn Reson Imaging Clin North Am 15(3): 433–448 viii

    Google Scholar 

  53. Park BK, Kim B, Kim CK, Lee HM, Kwon GY (2007) Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. J Comput Assist Tomogr 31(4): 534–538

    PubMed  Google Scholar 

  54. Beyersdorff D, Taymoorian K, Knosel T, Schnorr D, Felix R, Hamm B, Bruhn H (2005) MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR 185(5): 1214–1220

    PubMed  Google Scholar 

  55. Torricelli P, Cinquantini F, Ligabue G, Bianchi G, Sighinolfi P, Romagnoli R (2006) Comparative evaluation between external phased array coil at 3 T and endorectal coil at 1.5 T: preliminary results. J Comput Assist Tomogr 30(3): 355–361

    PubMed  Google Scholar 

  56. Kurhanewicz J, Vigneron DB, Hricak H, Parivar F, Nelson SJ, Shinohara K, Carroll PR (1996) Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 200(2): 489–496

    PubMed  CAS  Google Scholar 

  57. Costello LC, Franklin RB, Narayan P (1999) Citrate in the diagnosis of prostate cancer. Prostate 38(3): 237–245

    PubMed  CAS  Google Scholar 

  58. Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, Narayan P (1993) Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med 29(2): 149–157

    PubMed  CAS  Google Scholar 

  59. Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL (2007) Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 245: 499–506

    PubMed  Google Scholar 

  60. Kurhanewicz J, Vigneron DB, Nelson SJ (2000) Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia (New York, NY) 2(1–2): 166–189

    CAS  Google Scholar 

  61. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA (2005) Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234(3): 804–814

    PubMed  Google Scholar 

  62. Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB (2001) Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn Reson Med 46(6): 1079–1087

    PubMed  CAS  Google Scholar 

  63. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R (1998) Simultaneous in vivo spectral editing and water suppression. NMR Biomed 11(6): 266–272

    PubMed  CAS  Google Scholar 

  64. Tran TK, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson S, Hurd R (2000) Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 43(1): 23–33

    PubMed  CAS  Google Scholar 

  65. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 198(3): 795–805

    PubMed  CAS  Google Scholar 

  66. Males RG, Vigneron DB, Star-Lack J, Falbo SC, Nelson SJ, Hricak H, Kurhanewicz J (2000) Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 43(1): 17–22

    PubMed  CAS  Google Scholar 

  67. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll PR, Kurhanewicz J (2004) Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 233(3): 701–708

    PubMed  Google Scholar 

  68. Shukla-Dave A, Hricak H, Kattan MW, Pucar D, Kuroiwa K, Chen HN, Spector J, Koutcher JA, Zakian KL, Scardino PT (2007) The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 99(4): 786–793

    PubMed  CAS  Google Scholar 

  69. Coakley FV, Chen I, Qayyum A, Westphalen AC, Carroll PR, Hricak H, Chen MH, Kurhanewicz J (2007) Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU Int 99(1): 41–45

    PubMed  CAS  Google Scholar 

  70. Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M 3rd, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233(2): 441–448

    PubMed  Google Scholar 

  71. Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, Kelly WK, Hricak H, Zakian KL (2004) Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer 3(3): 174–181

    PubMed  Google Scholar 

  72. Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, Ebora LE, Scardino PT, Koutcher JA, Zakian KL (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236(2): 545–553

    PubMed  Google Scholar 

  73. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, Wood PJ, Noworolski S, Nelson SJ, Barken I, Carroll PR, Kurhanewicz J (2001) Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 46(1): 49–57

    PubMed  CAS  Google Scholar 

  74. Mueller-Lisse UG, Vigneron DB, Hricak H, Swanson MG, Carroll PR, Bessette A, Scheidler J, Srivastava A, Males RG, Cha I, Kurhanewicz J (2001) Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 221(2): 380–390

    PubMed  CAS  Google Scholar 

  75. Pickett B, Kurhanewicz J, Pouliot J, Weinberg V, Shinohara K, Coakley F, Roach M III (2006) Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys 65(1): 65–72

    PubMed  CAS  Google Scholar 

  76. Chen AP, Cunningham CH, Kurhanewicz J, Xu D, Hurd RE, Pauly JM, Carvajal L, Karpodinis K, Vigneron DB (2006) High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 24(7): 825–832

    PubMed  CAS  Google Scholar 

  77. Cunningham CH, Vigneron DB, Chen AP, Xu D, Nelson SJ, Hurd RE, Kelley DA, Pauly JM (2005) Design of flyback echo-planar readout gradients for magnetic resonance spectroscopic imaging. Magn Reson Med 54(5): 1286–1289

    PubMed  Google Scholar 

  78. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A (2007) Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology 245(2): 507–516

    PubMed  Google Scholar 

  79. Hosseinzadeh K, Schwarz SD (2004) Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 20(4): 654–661

    PubMed  Google Scholar 

  80. Sato C, Naganawa S, Nakamura T, Kumada H, Miura S, Takizawa O, Ishigaki T (2005) Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 21(3): 258–262

    PubMed  Google Scholar 

  81. Gibbs P, Pickles MD, Turnbull LW (2006) Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol 41(2): 185–188

    PubMed  Google Scholar 

  82. Issa B (2002) In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging 16(2): 196–200

    PubMed  Google Scholar 

  83. Shimofusa R, Fujimoto H, Akamata H, Motoori K, Yamamoto S, Ueda T, Ito H (2005) Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 29(2): 149–153

    PubMed  Google Scholar 

  84. Pruessmann KP, Weiger M, Scheidegger MB, Boesiger P (1999) SENSE: sensitivity encoding for fast MRI. Magn Reson Med 42(5): 952–962

    PubMed  CAS  Google Scholar 

  85. Sodickson DK, Griswold MA, Jakob PM (1999) SMASH imaging. Magn Reson Imaging Clin North Am 7(2): 237–254 vii–viii

    CAS  Google Scholar 

  86. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW (2006) Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging 23(2): 130–134

    PubMed  Google Scholar 

  87. Kim CK, Park BK, Lee HM, Kwon GY (2007) Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 42(12): 842–847

    PubMed  Google Scholar 

  88. Chen AP, Oh J, Han ET, Xu D, Kurhanewicz J, Vignerion DB (2006) Multi-parametric MR Imaging of Prostate Cancer at 3T. Seattle, p 1802

  89. Sinha S, Sinha U (2004) In vivo diffusion tensor imaging of the human prostate. Magn Reson Med 52(3): 530–537

    PubMed  Google Scholar 

  90. Manenti G, Carlani M, Mancino S, Colangelo V, Di Roma M, Squillaci E, Simonetti G (2007) Diffusion tensor magnetic resonance imaging of prostate cancer. Invest Radiol 42(6): 412–419

    PubMed  Google Scholar 

  91. Gurses B, Kabakci N, Kovanlikaya A, Firat Z, Bayram A, Ulueth AM, Kovanlikaya I (2007) Diffusion tensor imaging of the normal prostate at 3 Tesla. Eur Radiol

  92. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE (2004) Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging–initial experience. Radiology 233(3): 709–715

    PubMed  Google Scholar 

  93. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J (2005) Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med 53(2): 249–255

    PubMed  CAS  Google Scholar 

  94. Futterer JJ, Engelbrecht MR, Huisman HJ, Jager GJ, Hulsbergen-van De Kaa CA, Witjes JA, Barentsz JO (2005) Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 237(2): 541–549

    PubMed  Google Scholar 

  95. Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, Leach MO, Dearnaley DP, Husband JE (2000) Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55(2): 99–109

    PubMed  CAS  Google Scholar 

  96. Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, Leach MO, Husband JE (2001) Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology 218(2): 365–374

    PubMed  CAS  Google Scholar 

  97. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7(1): 91–101

    PubMed  CAS  Google Scholar 

  98. Buckley DL (2002) Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 47(3): 601–606

    PubMed  Google Scholar 

  99. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A (2001) Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 14(4): 457–463

    PubMed  CAS  Google Scholar 

  100. Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, de la Rosette JJ, Blickman JG, Barentsz JO (2003) Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 229(1): 248–254

    PubMed  Google Scholar 

  101. Kim CK, Park BK, Kim B (2006) Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr 30(1): 7–11

    PubMed  Google Scholar 

  102. Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, Choyke PL (2007) Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR 189(4): 849

    PubMed  Google Scholar 

  103. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70(2): 425–430

    PubMed  Google Scholar 

  104. Kurhanewicz J, Vigneron D, Carroll P, Coakley F (2008) Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 18(1): 71–77

    Article  PubMed  Google Scholar 

  105. Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, Moskowitz CS, Ishill NM, Reuter VE, Touijer K, Zakian KL, Koutcher JA (2008) Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging–correlation with pathologic findings. Radiology 246(2): 480–488

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medical Physics and Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

    Yousef Mazaheri & Amita Shukla-Dave

  2. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

    Ada Muellner & Hedvig Hricak

Authors
  1. Yousef Mazaheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amita Shukla-Dave
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ada Muellner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hedvig Hricak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yousef Mazaheri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mazaheri, Y., Shukla-Dave, A., Muellner, A. et al. MR imaging of the prostate in clinical practice. Magn Reson Mater Phy 21, 379–392 (2008). https://doi.org/10.1007/s10334-008-0138-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10334-008-0138-y

Keywords

Search

Navigation